Oncology Times - Ot Broadcasts From The Ipad Archives

Facebook Twitter Linkedin Reddit Word File Edit Insert View Format Table Tools Formats pWords: 89 Sample HTML Undo New page indentation compress encoding option ico option2 option3 option4 option5 option6 option7 option8Clean When the immune checkpoint inhibitor durvalumab was added to standard-of-care chemoradiation treatment for patients with limited-stage small-cell lung cancer, it brought a “statistically significant and clinically meaningful” improvement in overall and progression-free survival, compared to adding placebo. This was in data from the ADRIATIC study reported in the Plenary Session at the 2024 ASCO Annual Meeting in Chicago. Peter Goodwin was there for Oncology Times, where he talked with the lead author of the new research, David Spigel, MD, Chief Scientific Officer at Sarah Cannon Research Institute in Nashville, TN. Characters: 657 × Paste or compose your doc in the editor and switch to HTML view to get the code! Word Doc to HTML Online Converter Word Docum